Search results for: Pricing and Reimbursement
Filter search results
Multi-indication Pricing: Pros, Cons and Applicability to the UK
28 October 2015
…OHE Briefing on the topic of multi-indication pricing. The briefing contains a summary of a workshop organised and facilitated by OHE and MME Europe. Multi-indication pricing (MIP) involves setting a…
What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
19 November 2024
…In reality, indication launches within a country can be costly, with significant investment needed in regulatory and HTA submission and compliance, manufacturing and distribution adjustments, marketing and commercialisation, and any…
A Spotlight on Haemophilia Therapies
3 October 2024
…bodies must foster a supportive policy environment that recognises and rewards innovation, including intellectual property protection, transparent approval requirements and processes, and pricing and reimbursement policies that incentivise and reward…
Spotlight on OHE: Assessing Value and Balancing Needs in Health Care
15 December 2011
…Pricing and Reimbursement The OHE team addressed various aspects of pricing and reimbursement (P&R) during the last quarter of 2011. At the ISPOR Europe meeting in November, Adrian Towse and…
Update: Value-Based Pricing in the UK
11 January 2011
…replace the current PPRS system. The implications for pricing and reimbursement, and innovation, are outlined by Prof Towse in this blog post. Since the late 1950s, prices for medicines in…
Around the World in HTAs: Saudi Arabia – Navigating the healthcare and HTA landscape
24 September 2025
…Arabia requires navigating several steps: market authorisation, pricing, HTA, and reimbursement or procurement. Market authorisation is granted nationally by the Saudi Food and Drug Authority (SFDA), with four distinct approval…
Looking Further Afield – What Can Health Economics Learn from the Environmental Economics Approach to Discounting?
1 February 2024
…Limits to Substitution Between Ecosystem Services and Manufactured Goods and Implications for Social Discounting. Environmental and Resource Economics, 69(1), pp.135–158. 10.1007/s10640-016-0068-5. Freeman, M., Groom, B. and Spackman, M., 2018. Social…
New research reveals, in carers’ own words, the multidimensional burdenof caring for leukemia patients
20 November 2025
…and US, and 5 each from France, Germany, Italy and Spain – were asked questions about the patient’s diagnosis and how they became a carer, their experience of caregiving as…
The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe
2 June 2023
…consider i) pricing and reimbursement mechanisms, ii) standardising testing and care pathways, and iii) developing new infrastructure Share this: Download publication Next-generation sequencing (NGS) generates comprehensive and actionable information on…